{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:49:16Z","timestamp":1787240956391,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,15]]},"DOI":"10.7759\/cureus.58302","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T07:36:36Z","timestamp":1713166596000},"source":"Crossref","is-referenced-by-count":1,"title":["Understanding Antithrombotic Agents for Rehabilitation Therapy: A Comprehensive Narrative Review"],"prefix":"10.7759","author":[{"given":"Shuji","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rintaro","family":"Ohama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Hoei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Tojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.23736\/S1973-9087.23.07895-4","article-title":"Assessment of activities and participation of people by rehabilitation-focused clinical registries: a systematic scoping review","volume":"59","author":"Gutierrez-Arias R","year":"2023","unstructured":"Gutierrez-Arias R, Neculhueque-Zapata X, Valenzuela-Suazo R, et al.. Assessment of activities and participation of people by rehabilitation-focused clinical registries: a systematic scoping review. Eur J Phys Rehabil Med. 2023, 59:640-52. 10.23736\/S1973-9087.23.07895-4","journal-title":"Eur J Phys Rehabil Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21207609","article-title":"Pathophysiology and treatment of stroke: present status and future perspectives","volume":"21","author":"Kuriakose D","year":"2020","unstructured":"Kuriakose D, Xiao Z. Pathophysiology and treatment of stroke: present status and future perspectives. Int J Mol Sci. 2020, 21:10.3390\/ijms21207609","journal-title":"Int J Mol Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/17474930221090347","article-title":"Japan Stroke Society guideline 2021 for the treatment of stroke","volume":"17","author":"Miyamoto S","year":"2022","unstructured":"Miyamoto S, Ogasawara K, Kuroda S, et al.. Japan Stroke Society guideline 2021 for the treatment of stroke. Int J Stroke. 2022, 17:1039-49. 10.1177\/17474930221090347","journal-title":"Int J Stroke"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.121.036582","article-title":"Our efforts for ideal stroke prevention and treatment in japan","volume":"53","author":"Yamaguchi T","year":"2022","unstructured":"Yamaguchi T. Our efforts for ideal stroke prevention and treatment in japan. Stroke. 2022, 53:1030-6. 10.1161\/STROKEAHA.121.036582","journal-title":"Stroke"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2305367","article-title":"Comparative safety review of antithrombotic treatment options for patients with atrial fibrillation undergoing percutaneous coronary intervention","volume":"23","author":"Erbay MI","year":"2024","unstructured":"Erbay MI, Pyrpyris N, Susarla S, et al.. Comparative safety review of antithrombotic treatment options for patients with atrial fibrillation undergoing percutaneous coronary intervention. Expert Opin Drug Saf. 2024, 23:149-60. 10.1080\/14740338.2024.2305367","journal-title":"Expert Opin Drug Saf"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy807","article-title":"Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial","volume":"40","author":"Chao TF","year":"2019","unstructured":"Chao TF, Chen SA, Ruff CT, et al.. Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2019, 40:1518-27. 10.1093\/eurheartj\/ehy807","journal-title":"Eur Heart J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0737-1","article-title":"The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects","volume":"66","author":"Small DS","year":"2010","unstructured":"Small DS, Kothare P, Yuen E, et al.. The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects. Eur J Clin Pharmacol. 2010, 66:127-35. 10.1007\/s00228-009-0737-1","journal-title":"Eur J Clin Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-16-1337","article-title":"Current status and outcomes of direct oral anticoagulant use in real-world atrial fibrillation patients - Fushimi AF registry","volume":"81","author":"Yamashita Y","year":"2017","unstructured":"Yamashita Y, Uozumi R, Hamatani Y, et al.. Current status and outcomes of direct oral anticoagulant use in real-world atrial fibrillation patients - Fushimi AF registry. Circ J. 2017, 81:1278-85. 10.1253\/circj.CJ-16-1337","journal-title":"Circ J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2020.08.008","article-title":"Bleeding risks associated with anticoagulant therapies after percutaneous coronary intervention in japanese patients with ischemic heart disease complicated by atrial fibrillation: a comparative study","volume":"77","author":"Nakamura M","year":"2021","unstructured":"Nakamura M, Yamashita T, Hayakawa A, et al.. Bleeding risks associated with anticoagulant therapies after percutaneous coronary intervention in japanese patients with ischemic heart disease complicated by atrial fibrillation: a comparative study. J Cardiol. 2021, 77:186-94. 10.1016\/j.jjcc.2020.08.008","journal-title":"J Cardiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-019-01934-6","article-title":"Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings","volume":"48","author":"Ikeda T","year":"2019","unstructured":"Ikeda T, Ogawa S, Kitazono T, et al.. Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings. J Thromb Thrombolysis. 2019, 48:653-60. 10.1007\/s11239-019-01934-6","journal-title":"J Thromb Thrombolysis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2018.01.141","article-title":"The EXPAND study: efficacy and safety of rivaroxaban in Japanese patients with non-valvular atrial fibrillation","volume":"258","author":"Shimokawa H","year":"2018","unstructured":"Shimokawa H, Yamashita T, Uchiyama S, et al.. The EXPAND study: efficacy and safety of rivaroxaban in Japanese patients with non-valvular atrial fibrillation. Int J Cardiol. 2018, 258:126-32. 10.1016\/j.ijcard.2018.01.141","journal-title":"Int J Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/ehjqcco\/qcab025","article-title":"Two-year outcomes of more than 30 000 elderly patients with atrial fibrillation: results from the All Nippon AF In the elderly (ANAFIE) registry","volume":"8","author":"Yamashita T","year":"2022","unstructured":"Yamashita T, Suzuki S, Inoue H, et al.. Two-year outcomes of more than 30 000 elderly patients with atrial fibrillation: results from the All Nippon AF In the elderly (ANAFIE) registry. Eur Heart J Qual Care Clin Outcomes. 2022, 8:202-13. 10.1093\/ehjqcco\/qcab025","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.015439","article-title":"Relationship between platelet reactivity and ischemic and bleeding events after percutaneous coronary intervention in East Asian patients: 1-year results of the PENDULUM registry","volume":"9","author":"Nakamura M","year":"2020","unstructured":"Nakamura M, Kadota K, Takahashi A, et al.. Relationship between platelet reactivity and ischemic and bleeding events after percutaneous coronary intervention in East Asian patients: 1-year results of the PENDULUM registry. J Am Heart Assoc. 2020, 9:e015439. 10.1161\/JAHA.119.015439","journal-title":"J Am Heart Assoc"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.120.010007","article-title":"Patient selection and clinical outcomes in the STOPDAPT-2 trial: an all-comer single-center registry during the enrollment period of the STOPDAPT-2 randomized controlled trial","volume":"14","author":"Kanenawa K","year":"2021","unstructured":"Kanenawa K, Yamaji K, Tashiro H, Domei T, Ando K, Watanabe H, Kimura T. Patient selection and clinical outcomes in the STOPDAPT-2 trial: an all-comer single-center registry during the enrollment period of the STOPDAPT-2 randomized controlled trial. Circ Cardiovasc Interv. 2021, 14:e010007. 10.1161\/CIRCINTERVENTIONS.120.010007","journal-title":"Circ Cardiovasc Interv"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4244\/EIJ-D-20-00052","article-title":"Validation of the Academic Research Consortium for high bleeding risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores","volume":"16","author":"Ueki Y","year":"2020","unstructured":"Ueki Y, B\u00e4r S, Losdat S, et al.. Validation of the Academic Research Consortium for high bleeding risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores. EuroIntervention. 2020, 16:371-9. 10.4244\/EIJ-D-20-00052","journal-title":"EuroIntervention"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.119.008307","article-title":"Application of the academic research consortium high bleeding risk criteria in an all-comers registry of percutaneous coronary intervention","volume":"12","author":"Natsuaki M","year":"2019","unstructured":"Natsuaki M, Morimoto T, Shiomi H, et al.. Application of the academic research consortium high bleeding risk criteria in an all-comers registry of percutaneous coronary intervention. Circ Cardiovasc Interv. 2019, 12:e008307. 10.1161\/CIRCINTERVENTIONS.119.008307","journal-title":"Circ Cardiovasc Interv"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4244\/EIJ-D-20-00345","article-title":"High bleeding risk and clinical outcomes in East Asian patients undergoing percutaneous coronary intervention: the PENDULUM registry","volume":"16","author":"Nakamura M","year":"2021","unstructured":"Nakamura M, Kadota K, Nakao K, et al.. High bleeding risk and clinical outcomes in East Asian patients undergoing percutaneous coronary intervention: the PENDULUM registry. EuroIntervention. 2021, 16:1154-62. 10.4244\/EIJ-D-20-00345","journal-title":"EuroIntervention"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-20-1058","article-title":"Single antiplatelet therapy with prasugrel vs. dual antiplatelet therapy in Japanese percutaneous coronary intervention patients with high bleeding risk","volume":"85","author":"Nakamura M","year":"2021","unstructured":"Nakamura M, Kadota K, Nakao K, et al.. Single antiplatelet therapy with prasugrel vs. dual antiplatelet therapy in Japanese percutaneous coronary intervention patients with high bleeding risk. Circ J. 2021, 85:785-93. 10.1253\/circj.CJ-20-1058","journal-title":"Circ J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.110.233163","article-title":"Microparticles, vascular function, and atherothrombosis","volume":"109","author":"Rautou PE","year":"2011","unstructured":"Rautou PE, Vion AC, Amabile N, Chironi G, Simon A, Tedgui A, Boulanger CM. Microparticles, vascular function, and atherothrombosis. Circ Res. 2011, 109:593-606. 10.1161\/CIRCRESAHA.110.233163","journal-title":"Circ Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1253\/circj.cj-09-0019","article-title":"Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan","volume":"73","author":"Jinnai T","year":"2009","unstructured":"Jinnai T, Horiuchi H, Makiyama T, et al.. Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan. Circ J. 2009, 73:1498-503. 10.1253\/circj.cj-09-0019","journal-title":"Circ J"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3109\/00207454.2010.551431","article-title":"Effect of cilostazol administration on cerebral hemodynamics and rehabilitation outcomes in poststroke patients","volume":"121","author":"Matsumoto S","year":"2011","unstructured":"Matsumoto S, Shimodozono M, Miyata R, Kawahira K. Effect of cilostazol administration on cerebral hemodynamics and rehabilitation outcomes in poststroke patients. Int J Neurosci. 2011, 121:271-8. 10.3109\/00207454.2010.551431","journal-title":"Int J Neurosci"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2016.08.017","article-title":"Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: A meta-analysis of observational studies","volume":"118","author":"Laporte S","year":"2017","unstructured":"Laporte S, Chapelle C, Caillet P, et al.. Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: A meta-analysis of observational studies. Pharmacol Res. 2017, 118:19-32. 10.1016\/j.phrs.2016.08.017","journal-title":"Pharmacol Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.100912","article-title":"Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction","volume":"183","author":"Labos C","year":"2011","unstructured":"Labos C, Dasgupta K, Nedjar H, Turecki G, Rahme E. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. CMAJ. 2011, 183:1835-43. 10.1503\/cmaj.100912","journal-title":"CMAJ"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12552","article-title":"Platelet function defects and sertraline-induced bleeding: a case report","volume":"34","author":"Strumia M","year":"2020","unstructured":"Strumia M, Guerrero F, Maurel-Ribes A, Garcia C, Payrastre B, Bagheri H. Platelet function defects and sertraline-induced bleeding: a case report. Fundam Clin Pharmacol. 2020, 34:632-6. 10.1111\/fcp.12552","journal-title":"Fundam Clin Pharmacol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1737","article-title":"Risk of clinically relevant bleeding in warfarin-treated patients--influence of SSRI treatment","volume":"18","author":"Wallerstedt SM","year":"2009","unstructured":"Wallerstedt SM, Gleerup H, Sundstr\u00f6m A, Stigendal L, Ny L. Risk of clinically relevant bleeding in warfarin-treated patients--influence of SSRI treatment. Pharmacoepidemiol Drug Saf. 2009, 18:412-6. 10.1002\/pds.1737","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.008755","article-title":"Selective serotonin reuptake inhibitors and bleeding risk in anticoagulated patients with atrial fibrillation: an analysis from the ROCKET AF 2rial","volume":"7","author":"Quinn GR","year":"2018","unstructured":"Quinn GR, Hellkamp AS, Hankey GJ, et al.. Selective serotonin reuptake inhibitors and bleeding risk in anticoagulated patients with atrial fibrillation: an analysis from the ROCKET AF 2rial. J Am Heart Assoc. 2018, 7:e008755. 10.1161\/JAHA.118.008755","journal-title":"J Am Heart Assoc"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-021-02436-0","article-title":"Use of antiplatelet drugs and the risk of mortality in patients with COVID-19: a meta-analysis","volume":"52","author":"Kow CS","year":"2021","unstructured":"Kow CS, Hasan SS. Use of antiplatelet drugs and the risk of mortality in patients with COVID-19: a meta-analysis. J Thromb Thrombolysis. 2021, 52:124-9. 10.1007\/s11239-021-02436-0","journal-title":"J Thromb Thrombolysis"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1475","article-title":"Covid-19: aspirin does not improve survival for patients admitted to hospital, trial reports","volume":"373","author":"Iacobucci G","year":"2021","unstructured":"Iacobucci G. Covid-19: aspirin does not improve survival for patients admitted to hospital, trial reports. BMJ. 2021, 373:n1475. 10.1136\/bmj.n1475","journal-title":"BMJ"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants: Antithrombotic therapy and prevention of thrombosis, 9th Ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Garcia DA","year":"2012","unstructured":"Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: Antithrombotic therapy and prevention of thrombosis, 9th Ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012, 141:e24S-43S. 10.1378\/chest.11-2291","journal-title":"Chest"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.2450\/2015.0096-15","article-title":"The evolution of anticoagulant therapy","volume":"14","author":"Franchini M","year":"2016","unstructured":"Franchini M, Liumbruno GM, Bonfanti C, Lippi G. The evolution of anticoagulant therapy. Blood Transfus. 2016, 14:175-84. 10.2450\/2015.0096-15","journal-title":"Blood Transfus"},{"key":"ref31","article-title":"Adjusting the dose of low molecular weight heparins in renally impaired and obese patients","volume":"2","author":"Spinler S","year":"2004","unstructured":"Spinler S. Adjusting the dose of low molecular weight heparins in renally impaired and obese patients. Clin Adv Hematol Oncol. 2004, 2:270, 273-4.","journal-title":"Clin Adv Hematol Oncol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrtlng.2023.05.003","article-title":"Comparison of anticoagulation monitoring strategies for adults supported on extracorporeal membrane oxygenation: a systematic review","volume":"61","author":"Sun J","year":"2023","unstructured":"Sun J, Ma Y, Su W, et al.. Comparison of anticoagulation monitoring strategies for adults supported on extracorporeal membrane oxygenation: a systematic review. Heart Lung. 2023, 61:72-83. 10.1016\/j.hrtlng.2023.05.003","journal-title":"Heart Lung"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2007.06.004","article-title":"Heparin-induced thrombocytopenia","volume":"21","author":"Warkentin TE","year":"2007","unstructured":"Warkentin TE. Heparin-induced thrombocytopenia. Hematol Oncol Clin North Am. 2007, 21:589-607, v. 10.1016\/j.hoc.2007.06.004","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/bs.pmbts.2019.02.005","article-title":"Heparinoids danaparoid and sulodexide as clinically used drugs","volume":"163","author":"Dou H","year":"2019","unstructured":"Dou H, Song A, Jia S, Zhang L. Heparinoids danaparoid and sulodexide as clinically used drugs. Prog Mol Biol Transl Sci. 2019, 163:55-74. 10.1016\/bs.pmbts.2019.02.005","journal-title":"Prog Mol Biol Transl Sci"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1177\/10742484221145010","article-title":"Fondaparinux sodium: recent advances in the management of thrombosis","volume":"28","author":"Bauersachs RM","year":"2023","unstructured":"Bauersachs RM. Fondaparinux sodium: recent advances in the management of thrombosis. J Cardiovasc Pharmacol Ther. 2023, 28:10742484221145010. 10.1177\/10742484221145010","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2023.07.141","article-title":"An evidence-based approach to anticoagulation therapy comparing direct oral anticoagulants and vitamin k antagonists in patients with atrial fibrillation and bioprosthetic valves: a systematic review, meta-analysis, and network meta-analysis","volume":"206","author":"Suppah M","year":"2023","unstructured":"Suppah M, Kamal A, Saadoun R, et al.. An evidence-based approach to anticoagulation therapy comparing direct oral anticoagulants and vitamin k antagonists in patients with atrial fibrillation and bioprosthetic valves: a systematic review, meta-analysis, and network meta-analysis. Am J Cardiol. 2023, 206:132-50. 10.1016\/j.amjcard.2023.07.141","journal-title":"Am J Cardiol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2023.108097","article-title":"Efficacy and safety of argatroban in the management of acute ischemic stroke: A systematic literature review and meta-analysis","volume":"236","author":"Al-Salihi MM","year":"2024","unstructured":"Al-Salihi MM, Saha R, Ayyad A, et al.. Efficacy and safety of argatroban in the management of acute ischemic stroke: A systematic literature review and meta-analysis. Clin Neurol Neurosurg. 2024, 236:108097. 10.1016\/j.clineuro.2023.108097","journal-title":"Clin Neurol Neurosurg"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9030264","article-title":"Updates on anticoagulation and laboratory tools for therapy monitoring of heparin, vitamin K antagonists and direct oral anticoagulants","volume":"9","author":"Kumano O","year":"2021","unstructured":"Kumano O, Akatsuchi K, Amiral J. Updates on anticoagulation and laboratory tools for therapy monitoring of heparin, vitamin K antagonists and direct oral anticoagulants. Biomedicines. 2021, 9:10.3390\/biomedicines9030264","journal-title":"Biomedicines"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1161\/01.str.24.1.35","article-title":"Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment","volume":"24","author":"Adams HP Jr","year":"1993","unstructured":"Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke. 1993, 24:35-41. 10.1161\/01.str.24.1.35","journal-title":"Stroke"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215340","article-title":"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack","volume":"369","author":"Wang Y","year":"2013","unstructured":"Wang Y, Wang Y, Zhao X, et al.. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013, 369:11-9. 10.1056\/NEJMoa1215340","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.118.023978","article-title":"Optimal duration of aspirin plus clopidogrel after ischemic stroke or transient ischemic attack","volume":"50","author":"Rahman H","year":"2019","unstructured":"Rahman H, Khan SU, Nasir F, Hammad T, Meyer MA, Kaluski E. Optimal duration of aspirin plus clopidogrel after ischemic stroke or transient ischemic attack. Stroke. 2019, 50:947-53. 10.1161\/STROKEAHA.118.023978","journal-title":"Stroke"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1177\/1747493016632239","article-title":"Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: the samurai-nonvalvular atrial fibrillation (NVAF) study","volume":"11","author":"Arihiro S","year":"2016","unstructured":"Arihiro S, Todo K, Koga M, et al.. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: the samurai-nonvalvular atrial fibrillation (NVAF) study. Int J Stroke. 2016, 11:565-74. 10.1177\/1747493016632239","journal-title":"Int J Stroke"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212354","article-title":"Rivaroxaban administration after acute ischemic stroke: the RELAXED study","volume":"14","author":"Yasaka M","year":"2019","unstructured":"Yasaka M, Minematsu K, Toyoda K, et al.. Rivaroxaban administration after acute ischemic stroke: the RELAXED study. PLoS One. 2019, 14:e0212354. 10.1371\/journal.pone.0212354","journal-title":"PLoS One"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15967","article-title":"Kinetic-pharmacodynamic model of warfarin for prothrombin time-international normalized ratio in Japanese patients","volume":"90","author":"Hirai T","year":"2024","unstructured":"Hirai T, Aoyama T, Tsuji Y, Itoh T, Matsumoto Y, Iwamoto T. Kinetic-pharmacodynamic model of warfarin for prothrombin time-international normalized ratio in Japanese patients. Br J Clin Pharmacol. 2024, 90:828-36. 10.1111\/bcp.15967","journal-title":"Br J Clin Pharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/246809-understanding-antithrombotic-agents-for-rehabilitation-therapy-a-comprehensive-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T07:36:43Z","timestamp":1713166603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/246809-understanding-antithrombotic-agents-for-rehabilitation-therapy-a-comprehensive-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,15]]},"references-count":44,"URL":"https:\/\/doi.org\/10.7759\/cureus.58302","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,15]]}}}